Featured Research

from universities, journals, and other organizations

Cancer-Linked BRCA2 Gene Plays Previously Unsuspected Role In Cell Division

Date:
February 1, 2001
Source:
Wistar Institute
Summary:
The BRCA2 gene, linked to familial breast and ovarian cancers, plays an important and previously unsuspected role in human cell division, according to a new study by scientists at The Wistar Institute.

Philadelphia -- The BRCA2 gene, linked to familial breast and ovarian cancers, plays an important and previously unsuspected role in human cell division, according to a new study by scientists at The Wistar Institute. When the BRCA2 protein is inactivated, their experiments showed, cells are dramatically delayed in their progress through mitosis, the cell-division stage of the cell cycle. The find opens an entirely new line of thinking for researchers working to understand how BRCA2 can cause cancer when mutated. With fresh insights may come more effective, more targeted treatments.

The same study also identified a new gene, dubbed BRAF35, and established that the BRAF35 protein associates closely with BRCA2 in a previously unknown complex. As with BRCA2, when the BRAF35 protein is inactivated, progress through mitosis is significantly delayed, raising the question of whether BRAF35, too, might be responsible for some cancers. Indeed, the BRAF35 gene maps to a location on chromosome 19 where anomalies have reported in many ovarian cancers.

A report on the study appears in the January 26 issue of Cell.

"This study helps us not only to better understand what BRCA2 is doing, but it also identifies a new gene, BRAF35, that may be involved in breast and ovarian cancers," says Wistar assistant professor Ramin Shiekhattar, Ph.D., senior author on the study. "It provides researchers with a number of new places to look for answers to our questions about these cancers."

Previous studies of BRCA2 had suggested that the gene was involved in DNA repair, not cell division. Shiekhattar's findings do not argue with those earlier observations, but offer an additional scientific framework within which to explore BRCA2 and its function.

"The complex in which we find BRCA2 and BRAF35 might serve a dual purpose for the cell," Shiekhattar notes. "It could be involved in both processes, DNA repair and cell cycle progression. Evolution often finds a way to use these complexes as tools for more than one task, like an Allen wrench or a Swiss Army knife."

To establish that BRCA2 and BRAF35 are important in cell cycle progression, the scientists sought first to synchronize the replication cycle in a population of cells. To do this, they used a drug to arrest all of the cells at the same point in the cell division process, then removed the drug. They then neutralized the activity of BRCA2 and BRAF35 using customized antibodies specific to each of the proteins. Between 450 and 600 individual cells were injected with the antibodies in the experiments. They then compared these cells to control cells.

In the control cells, the researchers saw that 12 hours after removal of the synchronizing drug, about 80 percent of the cells had successfully moved through mitosis. But in both the BRCA2- and BRAF-neutralized cells, approximately 50 percent of the cells had been unable to progress through mitosis at the 12-hour mark.

Looking again at 14 hours, the scientists saw that about 90 percent of the experimental cells had moved through mitosis by then. A larger proportion of the neutralized cells continued to lag behind their control counterparts, but this figure did bring the experimental cells closer to the status of the control cells at that time mark. A kind of catch-up effect seemed to be in play.

"Interestingly, the effect of neutralizing these two proteins was a significant delay in mitosis, but it was not a full block of the cell-division process," says Shiekhattar. "The fact that both antibodies appeared to be doing exactly the same thing gave credence to the idea of a functional interaction between these two proteins and indicated they were involved in the same process."

The lead author on the study is Lihua Y. Marmorstein, Ph.D., of The Wistar Institute. The co-authors at Wistar are Alexander Kinev, Ph.D., Daniel A. Bochar, Ph.D., and Hideo Beniya, Ph.D.. Gordon K.T. Chan and Tim J. Yen of Fox Chase Cancer Center are co-authors, as is Jonathan A. Epstein with the University of Pennsylvania School of Medicine. Funding for the research was provided by The V Foundation and The W.W. Smith Charitable Trust.

The Wistar Institute is an independent nonprofit biomedical research institution dedicated to discovering the basic mechanisms underlying major diseases, including cancer and AIDS, and to developing fundamentally new strategies to prevent or treat them. The Institute is a National Cancer Institute-designated Cancer Center - one of the nation's first, funded continuously since 1968, and one of only ten focused on basic research. Founded in 1892, Wistar was the first institution of its kind devoted to medical research and training in the nation.


Story Source:

The above story is based on materials provided by Wistar Institute. Note: Materials may be edited for content and length.


Cite This Page:

Wistar Institute. "Cancer-Linked BRCA2 Gene Plays Previously Unsuspected Role In Cell Division." ScienceDaily. ScienceDaily, 1 February 2001. <www.sciencedaily.com/releases/2001/01/010129063914.htm>.
Wistar Institute. (2001, February 1). Cancer-Linked BRCA2 Gene Plays Previously Unsuspected Role In Cell Division. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2001/01/010129063914.htm
Wistar Institute. "Cancer-Linked BRCA2 Gene Plays Previously Unsuspected Role In Cell Division." ScienceDaily. www.sciencedaily.com/releases/2001/01/010129063914.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins